Sector News

Sanofi takes a chance on Provention’s diabetes drug with marketing deal

October 8, 2022
Life sciences

While teplizumab has the potential to be a new type of diabetes medicine, it’s had a checkered past, and the contingencies in the deal with Sanofi reflect that. In 2010, Eli Lilly and partner MacroGenics were developing the drug and decided to shelve it after a study failed to reduce insulin use in patients with recent-onset Type 1 diabetes.

Provention got interested as continuing academic studies suggested benefits for the drug and bought the rights in 2018. By 2019, the purchase seemed like a good bet as researchers published a study in The New England Journal of Medicine that found the drug could delay the onset of disease with a single 14-day course of treatment.

The trial included 76 relatives of Type 1 diabetes patients who were themselves at high risk of developing the disease. Many of the patients went on to be diagnosed with the condition, but the median time to diagnosis for patients taking teplizumab was four years, compared with two years in the placebo group. READ MORE

By Kristin Jensen

Sourc: biopharmadive.com

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.